- Home
- OPT vs STOK Comparison
OPT vs STOK Comparison
Compare OPT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- STOK
- Stock Information
- Founded
- OPT 1984
- STOK 2014
- Country
- OPT Australia
- STOK United States
- Employees
- OPT N/A
- STOK N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- OPT Health Care
- STOK Health Care
- Exchange
- OPT Nasdaq
- STOK Nasdaq
- Market Cap
- OPT 767.9M
- STOK 721.4M
- IPO Year
- OPT 2020
- STOK 2019
- Fundamental
- Price
- OPT $3.24
- STOK $12.03
- Analyst Decision
- OPT Strong Buy
- STOK Strong Buy
- Analyst Count
- OPT 1
- STOK 7
- Target Price
- OPT $12.00
- STOK $21.40
- AVG Volume (30 Days)
- OPT 39.0K
- STOK 405.8K
- Earning Date
- OPT 08-30-2024
- STOK 11-05-2024
- Dividend Yield
- OPT N/A
- STOK N/A
- EPS Growth
- OPT N/A
- STOK N/A
- EPS
- OPT N/A
- STOK N/A
- Revenue
- OPT $261,859.00
- STOK $16,742,999.00
- Revenue This Year
- OPT N/A
- STOK $91.67
- Revenue Next Year
- OPT $46,864.64
- STOK $5.45
- P/E Ratio
- OPT N/A
- STOK N/A
- Revenue Growth
- OPT N/A
- STOK 81.08
- 52 Week Low
- OPT $1.79
- STOK $3.77
- 52 Week High
- OPT $5.45
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- STOK 39.51
- Support Level
- OPT $4.02
- STOK $13.39
- Resistance Level
- OPT $4.18
- STOK $14.72
- Average True Range (ATR)
- OPT 0.22
- STOK 0.68
- MACD
- OPT -0.13
- STOK 0.03
- Stochastic Oscillator
- OPT 6.85
- STOK 7.24
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.